Cell therapy market size to grow by USD 21.061 billion from 2021 to 2026; Astellas Pharma Inc., Athersys Inc., among others, emerge as key vendors - Technavio

NEW YORK, April 12, 2023 /PRNewswire/ -- The cell therapy market size is forecasted to increase by USD 21.061 billion from 2021 to 2026, at a CAGR of 56.79%, according to the recent market study by Technavio. The growth of the market will be driven by the increasing prevalence of chronic diseases, limitations in traditional organ transplantations fueling demand for cell therapies, and increasing funding in cell-based research. Charts & data tables about market and segment sizes and forecast period (2022-2026) have been covered in this report. Download the Sample Report

Vendor Analysis

The global cell therapy market is fragmented and highly competitive due to the presence of several tier-1, tier-2, and tier-3 companies. The competition in the market is expected to intensify during the forecast period, with advances in R&D, M&A, and technological innovations. International players are expected to grow by acquiring regional or local players. They are expanding their presence in the market, especially in fast-developing countries in APAC, such as India, China, Japan, Malaysia, and Vietnam. The increased disposable income of people in these countries will make APAC an attractive market to launch new products. In addition, the market is witnessing strong research and development in the field of cell therapy, which is expected to help some new vendors enter the market. Some of the key vendors covered in the report include:

• Astellas Pharma Inc.
• Athersys Inc.
• Avita Medical Inc.
• BioCardia Inc.
• Bone Therapeutics SA
• Brainstorm Cell Therapeutics Inc.
• Bristol-Myers Squibb Co.
• Caladrius Biosciences Inc.
• Capricor Therapeutics Inc.
• Castle Creek Biosciences Inc.
• CellPraxis
• CellSeed Inc.
• Cellular Biomedicine Group Inc.
• Celyad Oncology SA
• Gilead Sciences Inc.
• Lineage Cell Therapeutics Inc.
• Mesoblast Ltd.
• Novartis AG
• Pharmicell Co. Ltd.
• Sanpower Group Co. Ltd.
• ThermoGenesis Holdings Inc.
• Vericel Corp.

Why Buy?

• Add credibility to strategy
• Analyzes competitor's offerings
• Get a holistic view of the market

Grow your profit margin with Technavio - Buy the Report

Key Benefits for Industry Players & Stakeholders – 

• The report offers information on the criticality of vendor inputs, including R&D, CAPEX, and technology.
• It also provides detailed analyses of the market's competitive landscape and vendors' product offerings.
• The report also provides a qualitative and quantitative analysis of vendors to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

Get a holistic overview of the cell therapy market by industry experts to evaluate and develop growth strategies. Download the Sample

Market Segmentation:

The market is segmented by type (autologous and allogenic), application (malignancies, musculoskeletal, cardiovascular, and others), and geography (North America, Europe, Asia, and Rest of World (ROW)).

• By type, the market growth in the autologous segment will be significant over the forecast period. The growth of the segment will be driven by factors such as increasing government funding for R&D, the rising prevalence of chronic diseases, and the increasing focus of vendors on developing effective cell therapy products. The growing focus of vendors on developing novel treatments for emerging applications such as cardiology and ophthalmology will further drive the growth of the segment.
• North America will account for 40% of the market growth during the forecast period. The growth of the regional market is driven by increased funding from governments and the growing number of regenerative medicine centers in the region. In addition, the increasing number of M&As among vendors will drive the growth of the cell therapy market in North America.

Market Dynamics:

Market Driver:

• Increasing prevalence of chronic diseases
• Limitations in traditional organ transplantations fueling demand for cell therapies
• Increasing funding in cell-based research

The market is driven by the increasing prevalence of chronic diseases. The prevalence of chronic diseases, such as heart diseases, diabetes, stroke, cancer, obesity, and arthritis, is on the rise globally. This can be attributed to the adoption of unhealthy lifestyle habits such as lack of exercise, poor nutrition intake, and substance abuse such as addiction to alcohol and tobacco. Most treatment options available for these conditions only focus on relieving symptoms without dealing with the cause of the condition. Regenerative medicines overcome the challenges of untreatable diseases by using new treatment methods such as processed cells for reconstructing tissues. These methods also reduce healthcare costs by eliminating the need for long-term hospitalization. Such benefits are increasing the adoption of cell therapies for the treatment of chronic diseases, which is driving the growth of the market.

Major Trends:

• Increasing focus on cell therapy products
• Strategic alliances
• Increasing focus on the development of drugs for emerging applications

There is a high unmet need for the treatment of oncology and musculoskeletal disorders. This has encouraged vendors to focus on developing cell therapies for emerging applications. For instance, Amgen is currently developing Blinatumomab, a Phase III candidate, for the treatment of B-cell Non-Hodgkin lymphoma. Also, Bristol-Myers Squibb reported positive results from its Phase II clinical trial of lenalidomide for the treatment of multiple myeloma. The drug is currently in its Phase III development stage. Similarly, many vendors are extensively conducting clinical trials on autologous cell therapy products for the treatment of musculoskeletal disorders. Such developments are expected to fuel the growth of the market during the forecast period.

Key Challenges:

• High cost and failure rate in clinical trials
• Strict regulatory approval for product launch
• Ethical concerns in stem cell research

The estimated cost between the preclinical developmental stage of a cell therapy product to its approval can go up to USD 1.5 billion. Hence, most small vendors or start-ups seek government or private funding. Besides, most of the therapies fail clinical trials due to safety and efficacy issues. In addition, the development of a robust proof-of-concept preclinical model can be expensive, as it involves immunomodulation to match the human immune system. Moreover, the difficulty in finding a sufficient number of patients results in delays and indirectly increases clinical trial costs. All these challenges will hinder the growth of the market during the forecast period.

Gain instant access to 17,000+ market research reports. 
Technavio's SUBSCRIPTION platform

What are the key data covered in this cell therapy market report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the cell therapy market between 2022 and 2026
• Precise estimation of the size of the cell therapy market and its contribution to the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the cell therapy market across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information about vendors
• Comprehensive analysis of factors that will challenge the growth of cell therapy market vendors

Related Reports:

• The cell and gene therapy market size is expected to increase by USD 9.97 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 20.15%. The market is segmented by type (cell therapy and gene therapy) and geography (North America, Europe, Asia, and Rest of World (ROW)).
• The autologous cell therapy market size is expected to increase by USD 4.11 billion from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 14.16%. The market is segmented by product (autologous stem cell therapy and autologous cellular immunotherapies) and geography (North America, Europe, APAC, MEA, and South America).

Browse through Technavio's Health Care Market Reports

Table of contents:

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
• Exhibit 06: Executive Summary – Chart on Market Segmentation by Application
• Exhibit 07: Executive Summary – Chart on Incremental Growth
• Exhibit 08: Executive Summary – Data Table on Incremental Growth
• Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 13: Market segments

• 3.3 Market size 2021

• 3.4 Market outlook: Forecast for 2021-2026 
• Exhibit 14: Chart on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 15: Data Table on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2021-2026 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

• 4.1 Five forces summary
• Exhibit 18: Five forces analysis - Comparison between 2021 and 2026

• 4.2 Bargaining power of buyers 
• Exhibit 19: Bargaining power of buyers – Impact of key factors in 2021 and 2026

• 4.3 Bargaining power of suppliers 
• Exhibit 20: Bargaining power of suppliers – Impact of key factors in 2021 and 2026

• 4.4 Threat of new entrants 
• Exhibit 21: Threat of new entrants – Impact of key factors in 2021 and 2026

• 4.5 Threat of substitutes 
• Exhibit 22: Threat of substitutes – Impact of key factors in 2021 and 2026

• 4.6 Threat of rivalry
• Exhibit 23: Threat of rivalry – Impact of key factors in 2021 and 2026

• 4.7 Market condition
• Exhibit 24: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Type

• 5.1 Market segments
• Exhibit 25: Chart on Type - Market share 2021-2026 (%)
• Exhibit 26: Data Table on Type - Market share 2021-2026 (%)

• 5.2 Comparison by Type
• Exhibit 27: Chart on Comparison by Type
• Exhibit 28: Data Table on Comparison by Type

• 5.3 Autologous - Market size and forecast 2021-2026 
• Exhibit 29: Chart on Autologous - Market size and forecast 2021-2026 ($ million)
• Exhibit 30: Data Table on Autologous - Market size and forecast 2021-2026 ($ million)
• Exhibit 31: Chart on Autologous - Year-over-year growth 2021-2026 (%)
• Exhibit 32: Data Table on Autologous - Year-over-year growth 2021-2026 (%)

• 5.4 Allogenic - Market size and forecast 2021-2026 
• Exhibit 33: Chart on Allogenic - Market size and forecast 2021-2026 ($ million)
• Exhibit 34: Data Table on Allogenic - Market size and forecast 2021-2026 ($ million)
• Exhibit 35: Chart on Allogenic - Year-over-year growth 2021-2026 (%)
• Exhibit 36: Data Table on Allogenic - Year-over-year growth 2021-2026 (%)

• 5.5 Market opportunity by Type 
• Exhibit 37: Market opportunity by Type ($ million)

6 Market Segmentation by Application

• 6.1 Market segments
• Exhibit 38: Chart on Application - Market share 2021-2026 (%)
• Exhibit 39: Data Table on Application - Market share 2021-2026 (%)

• 6.2 Comparison by Application 
• Exhibit 40: Chart on Comparison by Application
• Exhibit 41: Data Table on Comparison by Application

• 6.3 Malignancies - Market size and forecast 2021-2026 
• Exhibit 42: Chart on Malignancies - Market size and forecast 2021-2026 ($ million)
• Exhibit 43: Data Table on Malignancies - Market size and forecast 2021-2026 ($ million)
• Exhibit 44: Chart on Malignancies - Year-over-year growth 2021-2026 (%)
• Exhibit 45: Data Table on Malignancies - Year-over-year growth 2021-2026 (%)

• 6.4 Musculoskeletal - Market size and forecast 2021-2026 
• Exhibit 46: Chart on Musculoskeletal - Market size and forecast 2021-2026 ($ million)
• Exhibit 47: Data Table on Musculoskeletal - Market size and forecast 2021-2026 ($ million)
• Exhibit 48: Chart on Musculoskeletal - Year-over-year growth 2021-2026 (%)
• Exhibit 49: Data Table on Musculoskeletal - Year-over-year growth 2021-2026 (%)

• 6.5 Cardiovascular - Market size and forecast 2021-2026 
• Exhibit 50: Chart on Cardiovascular - Market size and forecast 2021-2026 ($ million)
• Exhibit 51: Data Table on Cardiovascular - Market size and forecast 2021-2026 ($ million)
• Exhibit 52: Chart on Cardiovascular - Year-over-year growth 2021-2026 (%)
• Exhibit 53: Data Table on Cardiovascular - Year-over-year growth 2021-2026 (%)

• 6.6 Others - Market size and forecast 2021-2026 
• Exhibit 54: Chart on Others - Market size and forecast 2021-2026 ($ million)
• Exhibit 55: Data Table on Others - Market size and forecast 2021-2026 ($ million)
• Exhibit 56: Chart on Others - Year-over-year growth 2021-2026 (%)
• Exhibit 57: Data Table on Others - Year-over-year growth 2021-2026 (%)

• 6.7 Market opportunity by Application 
• Exhibit 58: Market opportunity by Application ($ million)

7 Customer Landscape

• 7.1 Customer landscape overview 
• Exhibit 59: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

8 Geographic Landscape

• 8.1 Geographic segmentation 
• Exhibit 60: Chart on Market share by geography 2021-2026 (%)
• Exhibit 61: Data Table on Market share by geography 2021-2026 (%)

• 8.2 Geographic comparison 
• Exhibit 62: Chart on Geographic comparison
• Exhibit 63: Data Table on Geographic comparison

• 8.3 North America - Market size and forecast 2021-2026 
• Exhibit 64: Chart on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 65: Data Table on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 66: Chart on North America - Year-over-year growth 2021-2026 (%)
• Exhibit 67: Data Table on North America - Year-over-year growth 2021-2026 (%)

• 8.4 Europe - Market size and forecast 2021-2026 
• Exhibit 68: Chart on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 69: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 70: Chart on Europe - Year-over-year growth 2021-2026 (%)
• Exhibit 71: Data Table on Europe - Year-over-year growth 2021-2026 (%)

• 8.5 Asia - Market size and forecast 2021-2026 
• Exhibit 72: Chart on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 73: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 74: Chart on Asia - Year-over-year growth 2021-2026 (%)
• Exhibit 75: Data Table on Asia - Year-over-year growth 2021-2026 (%)

• 8.6 Rest of World (ROW) - Market size and forecast 2021-2026 
• Exhibit 76: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 77: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 78: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
• Exhibit 79: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)

• 8.7 US - Market size and forecast 2021-2026 
• Exhibit 80: Chart on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 81: Data Table on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 82: Chart on US - Year-over-year growth 2021-2026 (%)
• Exhibit 83: Data Table on US - Year-over-year growth 2021-2026 (%)

• 8.8 Germany - Market size and forecast 2021-2026 
• Exhibit 84: Chart on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 85: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 86: Chart on Germany - Year-over-year growth 2021-2026 (%)
• Exhibit 87: Data Table on Germany - Year-over-year growth 2021-2026 (%)

• 8.9 UK - Market size and forecast 2021-2026 
• Exhibit 88: Chart on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 89: Data Table on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 90: Chart on UK - Year-over-year growth 2021-2026 (%)
• Exhibit 91: Data Table on UK - Year-over-year growth 2021-2026 (%)

• 8.10 China - Market size and forecast 2021-2026 
• Exhibit 92: Chart on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 93: Data Table on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 94: Chart on China - Year-over-year growth 2021-2026 (%)
• Exhibit 95: Data Table on China - Year-over-year growth 2021-2026 (%)

• 8.11 Japan - Market size and forecast 2021-2026 
• Exhibit 96: Chart on Japan - Market size and forecast 2021-2026 ($ million)
• Exhibit 97: Data Table on Japan - Market size and forecast 2021-2026 ($ million)
• Exhibit 98: Chart on Japan - Year-over-year growth 2021-2026 (%)
• Exhibit 99: Data Table on Japan - Year-over-year growth 2021-2026 (%)

• 8.12 Market opportunity by geography 
• Exhibit 100: Market opportunity by geography ($ million)

9 Drivers, Challenges, and Trends

• 9.1 Market drivers

• 9.2 Market challenges

• 9.3 Impact of drivers and challenges 
• Exhibit 101: Impact of drivers and challenges in 2021 and 2026

• 9.4 Market trends

10 Vendor Landscape

• 10.1 Overview

• 10.2 Vendor landscape
• Exhibit 102: Overview on Criticality of inputs and Factors of differentiation

• 10.3 Landscape disruption
• Exhibit 103: Overview on factors of disruption

• 10.4 Industry risks
• Exhibit 104: Impact of key risks on business

11 Vendor Analysis

• 11.1 Vendors covered
• Exhibit 105: Vendors covered

• 11.2 Market positioning of vendors 
• Exhibit 106: Matrix on vendor position and classification

• 11.3 Astellas Pharma Inc.
• Exhibit 107: Astellas Pharma Inc. - Overview
• Exhibit 108: Astellas Pharma Inc. - Product / Service
• Exhibit 109: Astellas Pharma Inc. - Key news
• Exhibit 110: Astellas Pharma Inc. - Key offerings

• 11.4 BioCardia Inc.
• Exhibit 111: BioCardia Inc. - Overview
• Exhibit 112: BioCardia Inc. - Key offerings

• 11.5 Bone Therapeutics SA
• Exhibit 113: Bone Therapeutics SA - Overview
• Exhibit 114: Bone Therapeutics SA - Product / Service
• Exhibit 115: Bone Therapeutics SA - Key offerings

• 11.6 Bristol-Myers Squibb Co. 
• Exhibit 116: Bristol-Myers Squibb Co. - Overview
• Exhibit 117: Bristol-Myers Squibb Co. - Product / Service
• Exhibit 118: Bristol-Myers Squibb Co. - Key offerings

• 11.7 Castle Creek Biosciences Inc. 
• Exhibit 119: Castle Creek Biosciences Inc. - Overview
• Exhibit 120: Castle Creek Biosciences Inc. - Product / Service
• Exhibit 121: Castle Creek Biosciences Inc. - Key offerings

• 11.8 CellPraxis
• Exhibit 122: CellPraxis - Overview
• Exhibit 123: CellPraxis - Product / Service
• Exhibit 124: CellPraxis - Key offerings

• 11.9 Gilead Sciences Inc.
• Exhibit 125: Gilead Sciences Inc. - Overview
• Exhibit 126: Gilead Sciences Inc. - Business segments
• Exhibit 127: Gilead Sciences Inc. - Key news
• Exhibit 128: Gilead Sciences Inc. - Key offerings
• Exhibit 129: Gilead Sciences Inc. - Segment focus

• 11.10 Novartis AG
• Exhibit 130: Novartis AG - Overview
• Exhibit 131: Novartis AG - Business segments
• Exhibit 132: Novartis AG - Key offerings
• Exhibit 133: Novartis AG - Segment focus

• 11.11 Sanpower Group Co. Ltd. 
• Exhibit 134: Sanpower Group Co. Ltd. - Overview
• Exhibit 135: Sanpower Group Co. Ltd. - Product / Service
• Exhibit 136: Sanpower Group Co. Ltd. - Key offerings

• 11.12 Vericel Corp.
• Exhibit 137: Vericel Corp. - Overview
• Exhibit 138: Vericel Corp. - Business segments
• Exhibit 139: Vericel Corp. - Key news
• Exhibit 140: Vericel Corp. - Key offerings
• Exhibit 141: Vericel Corp. - Segment focus

12 Appendix

• 12.1 Scope of the report

• 12.2 Inclusions and exclusions checklist 
• Exhibit 142: Inclusions checklist
• Exhibit 143: Exclusions checklist

• 12.3 Currency conversion rates for US$ 
• Exhibit 144: Currency conversion rates for US$

• 12.4 Research methodology
• Exhibit 145: Research methodology
• Exhibit 146: Validation techniques employed for market sizing
• Exhibit 147: Information sources

• 12.5 List of abbreviations 
• Exhibit 148: List of abbreviations

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED